###### Significance of this study

What is already known on this subject?
======================================

-   Recipients of liver transplantation can be infected with SARS-CoV-2.

-   The outcome of COVID-19 of these immunosuppressed patients is not well known.

What are the new findings?
==========================

-   In our European cohort of liver transplant patients, overall and in-hospital fatality rates were 12% (95% CI 5% to 24%) and 17% (95% CI 7% to 32%), respectively. All deaths occurred in hospitalised patients.

-   Immunosuppressants were not discontinued in the vast majority of liver transplant recipients with COVID-19 infection.

How might it impact on clinical practice in the foreseeable future?
===================================================================

-   Patients infected in the first year after transplantation are presenting with less symptoms.

-   A history of cancer was more frequent in liver transplant recipient with poorer outcome, suggesting that higher attention should be paid in these patients.

Introduction {#s1}
============

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a virus belonging to the Orthocoronavirinae subfamily, first identified in Wuhan, Hubei Province, China, in December 2019.[@R1] Infection with SARS-CoV-2 is responsible for a clinical condition, named COVID-19, which ranges from mild respiratory and/or GI symptoms to interstitial pneumonia with acute respiratory distress syndrome (ARDS), diffuse thrombotic and thromboembolic disease,[@R2] multiorgan failure (MOF) and even death with a case fatality rate ranging from 5.65%[@R3] to 15%,[@R4] with high geographical heterogeneity. The outbreak of SARS-CoV-2 infection, declared pandemic on 11 March 2020 by the WHO,[@R6] has rapidly become a public health matter with several unmet issues. To date, firm knowledge on disease evolution, risk factors, clinical manifestations and optimal management are lacking, particularly in specific categories of patients. In the setting of solid organ transplantation, and particularly liver transplant recipients, information on natural history of COVID-19 are limited to expert statements,[@R7] case reports[@R9] and small case series.[@R10] Concerns have been raised about immunosuppression therapy, and it is still unknown whether the latter actually represents an increased risk for more severe illness, including higher risk of bacterial coinfection,[@R12] or not. In this view, previous experience with similar viruses, such as SARS-CoV in 2003[@R14] and MERS-CoV in 2015,[@R15] suggests that solid organ recipients would be prone to have increased morbidity.[@R16] However, in these cases, sample size and data quality did not allow definitive conclusion. Moreover, recent evidence has shown SARS-CoV-2 associated liver injury,[@R17] which might per se impair the prognosis of liver transplant patients with COVID-19. Overall, liver transplant patients are a population with multiple potential risk factors for poorer outcome that need to be investigated in detail.

This study describes the demographics, baseline clinical characteristics and early outcomes of a European cohort of liver transplant recipients with SARS-CoV-2 confirmed infection during the first outbreak of COVID-19 pandemic.

Methods {#s2}
=======

Study design {#s2-1}
------------

We conducted a European multicentre prospective cohort study recruiting consecutive liver transplant recipients from 19 secondary and tertiary (with more than 100 patients in regular follow-up) liver transplant centres across Europe. The coordinating centre was the Inselspital, University Hospital of Berne (KEK Approval Project ID 2020-00682). Written informed consent was obtained from all the included patients. The recruitment was conducted from 10 March to 10 May 2020.

Study population {#s2-2}
----------------

Consecutive adult (aged \>18 years at the time of SARS-CoV-2 infection) liver transplant recipients with concomitant confirmed SARS-CoV-2 infection were included in the study. The definition of confirmed SARS-CoV-2 infection was made according to the WHO guidelines and based on the presence of a laboratory assay proving SARS-CoV-2 infection, irrespective of clinical signs and symptoms of the disease.[@R20] Nucleic acid amplification test (NAAT) positive for SARS-CoV-2 in nasopharyngeal swab, sputum samples and bronchoalveolar lavage (BAL) was considered diagnostic. Typical radiological findings included bilateral, peripheral, consolidation and/or ground glass opacities, detected by using chest X-ray or thorax-CT scan.[@R21]

Patients were enrolled in the study at the time of diagnosis of COVID-19 and were followed up until death or 10 May 2020.

Baseline information regarding indication to liver transplantation, underlying liver disease and comorbidities, as well as anthropometric data were collected. At the time of COVID-19 diagnosis, clinical features and laboratory parameters were recorded. All laboratory and imaging investigations were performed as part of standard care of patients. Information on management of baseline immunosuppression, namely, its reduction or discontinuation, as well as specific pharmacological therapies and ventilation support, were obtained.

Patients were classified according to the severity of COVID-19 disease in outpatient care and hospitalisation, respectively.[@R13] Time from liver transplantation was classified as very long term (more than 10 years from liver transplant)[@R10] and very short term (1 year or less from liver transplant), whereas the terms long and short term were adopted if the patients had been transplanted for more or less than 5 years, respectively.[@R22] Management of single immunosuppression therapy was classified as follows: no change, reduction or discontinuation. For patients on double immunosuppression, reduction was defined as reduction of at least one immunosuppressive drug and/or discontinuation of one medication, while discontinuation was defined as discontinuation of both drugs.

The main outcome was patient death, while secondary outcomes were ARDS diagnosis[@R23] and hospitalisation. All the data were entered in an electronic dataset using a standardised case report form.

Patient and public involvement {#s2-3}
------------------------------

Patients or the public were not involved in the design, or conduct, or reporting or dissemination plans of our research.

Statistical analysis {#s2-4}
--------------------

Descriptive analysis of quantitative variables normally distributed were expressed as mean (number and %) and SD, whereas not-normally distributed variables were shown as median and IQR. Comparison of quantitative variables between two groups was performed using the t-test or non-parametric tests, according to the normality of the distribution. Comparison of proportions was performed using the Fisher's exact test. Missed data were not imputed, and all the analysis was performed only on non-missing data. P value less than 0.05 was considered statistically significant. SPSS software (V.25; IBM) was used for statistical analysis.

Results {#s3}
=======

Demographics and general characteristics of study population {#s3-1}
------------------------------------------------------------

Among 19 centres from seven European countries involved in the study, 12 registered at least one case. Of the 11 790 liver transplant recipient in regular follow-up overall, 91 patients were reported, of whom 57 were classified as confirmed cases and considered for statistical analysis ([figure 1](#F1){ref-type="fig"}). Overall, 40 recipients (70%) were male and median age (IQR) at diagnosis was 65 (57--70) years. Mean body mass index (BMI, kg/m^2^) was 26.0±4.6, with 23 (43%) and 8 (14%) patients being overweight and obese, respectively. Eleven (19%) and 21 (37%) subjects were defined as very short-term and very long-term transplant recipients, respectively. Additionally, median time (IQR) from transplant to COVID-19 diagnosis was 6 (2--13) years, and 32 (56%) patients had been transplanted more than 5 years before COVID-19 diagnosis. Characteristics related to indication for liver transplantation and underlying liver disease are summarised in [table 1](#T1){ref-type="table"}. With regard to comorbidities, 21 (37%) and 10 (18%) patients had one and more than one cardiovascular (CV) disease, respectively. In terms of CV risk factors, 32 (56%) recipients had arterial hypertension, and 21 (37%) diabetes mellitus, while 7 (12%) were active or former smokers. Sixteen (28%) patients had chronic kidney disease. Furthermore, 24 (42%) subjects had a clinical history of neoplasia (20 with hepatocellular carcinoma (HCC)), which was active in 5 (9%) patients. Concomitant respiratory diseases were found in 13 (23%) patients. Only one patient was HIV positive. Concerning pharmacological therapy for CV prevention, 13 (23%) recipients were on ACE inhibitors or sartans, while 9 (16%) were on low-dose aspirin.

![Flowchart of the study design.](gutjnl-2020-321923f01){#F1}

###### 

Demographic characteristics of liver transplant recipient with SARS-CoV-2 infection

  Study population                                         Results
  -------------------------------------------------------- -------------
  Patients, n                                              57
  Sex, male, n (%)                                         40 (70)
  Ethnicity, Caucasian, n (%)                              53 (93)
  Age, years, median (IQR)                                 65 (57--70)
   Age ≥65, n (%)                                          29 (51)
   Age \<65, n (%)                                         28 (49)
  BMI, kg/m^2^, mean (SD)                                  26.0±4.6
  BMI, classes, n (%)                                       
   18--24.9                                                23 (43)
   25--29.9                                                23 (43)
   \>30                                                    8 (14)
  Time from transplant to diagnosis, years, median (IQR)   6 (2--13)
   Very long-term transplant recipients, n (%)              21 (37)
   Very short-term transplant recipients, n (%)            11 (19)
   Long-term transplant recipients, n (%)                  32 (56)
  Indication to LT, n (%)                                   
   End-stage liver disease                                 38 (68)
   Liver tumour                                            16 (29)
   Acute liver failure                                     4 (7)
   Other                                                   9 (16)
  Underlying liver disease, n (%)                           
   ALD                                                     15 (26)
   Viral                                                   24 (42)
    HCV                                                    11 (19)
    HBV                                                    13 (23)
   PSC                                                     3 (5)
   PBC                                                     4 (7)
   NAFLD/NASH                                              2 (4)
   Autoimmune                                              1 (2)
   Hemochromatosis                                         1 (2)
   Wilson's disease                                        1 (2)
   Other                                                   10 (18)
  HCC, yes, n (%)                                          20 (35)
  Comorbidities, n (%)                                      
   Cardiovascular disease                                  21 (37)
    Coronary artery disease                                7 (12)
    Heart failure                                          9 (16)
    Atrial fibrillation                                    6 (11)
    Stroke                                                 1 (2)
    Other                                                  8 (14)
    \>1 cardiovascular disease                             10 (18)
   Arterial hypertension                                   32 (56)
   Diabetes mellitus                                       21 (37)
   Active cancer                                           5 (9)
   Kidney insufficiency                                    16 (28)
   Respiratory disease                                     13 (23)
    COPD                                                   7 (12)
    HIV                                                    1 (2)
  Smoke history, yes, n (%)                                7 (12)
  Symptoms at presentation, n (%)                           
   Fever                                                   44 (79)
   Cough                                                   31 (55)
   Dyspnoea                                                26 (46)
   Fatigue and myalgia                                     32 (56)
   GI symptoms                                             18 (33)
    Diarrhoea                                              16 (28)
    Abdominal pain                                         1 (2)
    Vomiting                                               1 (2)
   Anosmia or dysgeusia                                    4 (7)
   Other                                                   8 (14)
  Concomitant bacterial infection, n (%)                   9 (16)
   Suspected                                               3 (6)
   Confirmed                                               6 (11)

ALD, alcoholic liver disease; BMI, body mass index; COPD, chronic obstructive pulmonary disease; HCC, hepatocellular carcinoma; LT, liver transplantation; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.

When we considered very-long term recipients in terms of comorbidities, CV disease (57% vs 25%, respectively; p=0.023) and arterial hypertension (76% vs 44%; p=0.028) were significantly more frequent.

Presentation of COVID-19 in liver transplant patients {#s3-2}
-----------------------------------------------------

At the time of diagnosis, the most commonly self-reported symptoms were fever (44 patients, 79%), cough (31 patients, 55%), dyspnoea (26 patients, 46%), fatigue or myalgia (32 patients, 56%), anosmia or dysgeusia (4 patients, 7%), as well as GI symptoms (18 patients, 33%). Patients who experienced the latter often had more than one GI symptom, diarrhoea being the most frequently reported (16 patients). Other unspecific symptoms included loss of appetite (four patients), headache (one patients) and sore throat (one patient), while confusion and delirium were reported in two hospitalised patients.

When long-term and short-term recipients were compared in terms of symptoms at presentation, fever (91% vs 63%, respectively; p=0.019) and dyspnoea (59% vs 29%; p=0.032) were significantly more frequent among long-term recipients.

When very short-term recipients were considered, fever (50% vs 85%, respectively; p=0.045) and cough (27% vs 62%, p=0.048) were significantly less prevalent ([table 2](#T2){ref-type="table"}).

###### 

Differential distribution of symptoms between long-term and short-term liver transplant patients

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Symptoms,\                 Overall       Long-term transplant recipient   P value       Very-short term transplant recipient   P value                     
  n (%)                                                                                                                                                      
  -------------------------- ------------- -------------------------------- ------------- -------------------------------------- ------------- ------------- -----------
  Sex, male                  40 (70)       19 (48)                          21 (53)       0.561                                  10 (25%)      30 (75%)      0.146

  Age, years, median (IQR)   65 (57--70)   59 (53--65)                      68 (61--76)   **\<0.001**                            55 (52--70)   65 (59--72)   0.058

  BMI, kg/m^2^, mean (SD)    26.0±4.6      26.1±4.6                         25.7±5.1      0.563                                  26.8±5.7      25.3±3.6      **0.043**

  Fever                      44 (79)       15 (63)                          29 (91)       **0.005**                              6 (55)        38 (84)       **0.045**

  Cough                      31 (55)       11 (46)                          20 (63)       0.280                                  3 (27)        28 (62)       **0.048**

  Dyspnoea                   26 (46)       7 (29)                           19 (59)       **0.032**                              3 (27)        23 (51)       0.192

  Fatigue                    32 (56)       11 (44)                          21 (66)       0.117                                  4 (36)        28 (61)       0.184

  Conjunctivitis             0             --                               --            --                                     --            --            --

  Anosmia/dysgeusia          4 (7)         0                                4 (13)        0.131                                  0             4 (9)         0.573

  GI                         18 (33)       6 (25)                           12 (38)       0.394                                  1 (9)         17 (38)       0.084

  Other                      8 (14)        3 (13)                           5 (16)        1.000                                  1 (9)         7 (16)        1.000
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

In the entire population, the diagnosis of SARS-CoV-2 infection was confirmed by NAAT positivity in nasopharyngeal swab, while one additional patients received BAL. Concerning radiological findings, CT scan and pulmonary radiography showed typical features of the disease in 24 (43%) and 23 (40%) cases, respectively.

The main laboratory findings are summarised in [table 3](#T3){ref-type="table"}. Four patients (8%) displayed relevant increase in liver enzymes (AST and/or ALT\>2 × ULN). Conversely, median (IQR) leucocytes, lymphocytes and thrombocytes were 4.5 (3.3--6.0)×1000/µL, 0.79 (0.40--1.10)×1000/µL and 160 (91--268)×1000/μL, respectively.

###### 

Initial laboratory data of liver transplant recipient with SARS-CoV-2 infection

                                                     Patients tested, n (%)   Results               Patients with value, n
  -------------------------------------------------- ------------------------ --------------------- ------------------------
  Blood counts, median (IQR)                                                                        
   Leucocytes (×1000/μL)                             51 (90)                  4.50 (3.33--6.00)     17 (33)\*
   Platelets (×1000/μL)                              49 (86)                  160 (91--268)         17 (35)\*
   Lymphocytes (×1000/μL)                            49 (86)                  0.79 (0.40--1.10)     37 (76)\*
  Biochemical and liver-related test, median (IQR)                                                  
   AST (U/L)                                         49 (86)                  38 (25--53)           13 (26)†
   ALT (U/L)                                         49 (86)                  30 (20--42)           10 (20)†
   GGT (U/L)                                         45 (79)                  66 (39--161)          29 (64)†
   ALP (U/L)                                         37 (65)                  97 (74--171)          9 (24)†
   Total bilirubin (mg/dL)                           43 (75)                  0.70 (0.48--1.09)     10 (23)†
   INR (ratio)                                       42 (74)                  1.10 (1.03--1.28)     14 (33)†
   Albumin (g/L)                                     19 (33)                  32 (29.5--36.5)       8 (42)\*
   Creatinine (mg/dL)                                50 (88)                  1.16 (0.93--1.55)     20 (40)†
   Glucose (mg/dL)                                   36 (63.2)                127.5 (92.5--163.0)   24 (67)†
  Inflammatory-related markers, median (IQR)                                                        
   D-Dimer (ng/mL)                                   17 (29.8)                871 (380--1739)       10 (59)†
   LDH (U/L)                                         31 (54.4)                273 (192--384)        20 (65)†
   IL-6 (pg/L)                                       9 (15.8)                 93 (59--288)          --
   Ferritin (ng/mL)                                  13 (22.8)                567 (171--1194)       9 (69)†

\*Below reference.

†Above reference.

ALP, alanine alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; IL-6, interleukin-6; INR, international normalised ratio; LDH, lactate dehydrogenase.

Concomitant bacterial infection was described in nine patients (16%). Three (6%) of them were defined suspected, since no confirmatory positive cultures were available, although clinical and laboratory findings were suggestive (symptomatic urinary infection, cholangitis and pulmonary coinfection) and six (11%) cases were defined as confirmed (positive blood culture). Gram-positive concomitant infection was found in three patients, while one patient resulted to be infected by Gram-negative strains and two subjects by both Gram-positive and Gram-negative strains. The most common Gram-negative strains belonged to Enterobacteriaceae (two *Escherichia coli*, one *Enterobacter cloacae*), whereas between Gram-positive strains enterococci were the most reported.

Management of immunosuppression therapy and COVID-19 therapy {#s3-3}
------------------------------------------------------------

Baseline immunosuppression therapy and its management are described in [table 4](#T4){ref-type="table"}. Overall, reduction was observed in 22 (39%) patients, and complete discontinuation was reported in 4 cases (7%). Considering individual therapies, antimetabolites were the most frequently discontinued drugs (18%), whereas calcineurin inhibitors (CNIs) were the most frequently reduced ones (16%).

###### 

Baseline immunosuppression characteristics and modification during the infection

  Baseline immunosuppression therapy   Overall, n (%)   No modification, n (%)   Reduction, n (%)   Discontinuation, n (%)
  ------------------------------------ ---------------- ------------------------ ------------------ ------------------------
  *Single agent*                                                                                    
  CNIs                                 16 (28)          12 (75)                  2 (12.5)           2 (12.5)
   Cyclosporine                        3 (5)            2 (67)                   0                  1 (33)
   Tacrolimus                          13 (29)          10 (77)                  2 (15)             1 (8)
  mTORi                                2 (4)            1 (50)                   0                  1 (50)
   Everolimus                          1 (2)            1 (100)                  0                  0
   Sirolimus                           1 (2)            0                        0                  1 (100)
  MMF                                  2 (3)            0                        0                  1 (100)
  Steroid                              1 (2)            1 (100)                  0                  0
  *Two or more agents*                                                                              
  CNIs+MMF                             21 (37)          7 (33)                   6 (29)             8 (38)
   CNIs                                --               --                       5                  1
   MMF                                 --               --                       1                  7
  CNIs+mTORi                           3 (5)            1 (33.3)                 1 (33.3)           1 (33.3)
   CNIs                                --               --                       1                  0
   mTORi                               --               --                       0                  1
  CNIs+steroids                        9 (16)           1 (11.2)                 4 (44.4)           4 (44.4)
   CNIs                                --               --                       4                  4
   Steroids                            --               --                       0                  0
  CNIs+AZA                             1 (2)            1 (100)                  0                  0
  mTORi +MMF                           2 (3)            1 (50)                   0                  1 (50)
   mTOR                                --               --                       0                  1
   MMF                                 --               --                       0                  0

AZA, azathioprine; CNIs, calcineurin inihibitors, including cyclosporine and tacrolimus; MMF, mycophenolate mofetil; mTORi, mammalian target of rapamycin inhibitor, including sirolimus and everolimus.

Concerning specific therapy for COVID-19, 19 (35%) patients received steroids, 22 (44%) hydroxychloroquine and 5 (9%) antivirals, including lopinavir/ritonavir (3 patients), darunavir/cobicistat and remdesivir. Only one patient was treated with tocilizumab, while two more patients were on immunomodulatory therapies because of concomitant comorbities (one on rituximab for active lymphoma and the other one on ruxolitinib for a graft vs host disease). Overall, 35 (63%) and 16 (29%) subjects received at least one and more than one antibiotic drug, respectively. Of those, 15 (27%) were treated with azithromycin as part of the standard care of COVID-19 therapy in some centres.[@R24]

As for respiratory support, oxygen therapy was required in more than half of the patients (30, 54%). Of those, the majority required only oxygen therapy through nasal cannula (18 patients, 32%), whereas 8 (14%) subjects received high-flow oxygen. Four (7%) patients required intubation and invasive mechanical ventilation ([table 5](#T5){ref-type="table"}).

###### 

Therapeutic strategies for COVID-19 and outcomes

  Study population                              Results
  --------------------------------------------- -------------
  Patients, n                                   57
  *Medications, n (%*)                          
  Steroids (for COVID-19)                       19 (35)
  Antibiotics                                   35 (63)
   Azitromycin                                  15 (27)
   \>1 antibiotic                               16 (29)
  Antivirals                                    5 (9)
   Lopinavir/ritonavir                          3 (5)
   Darunavir/cobicistat                         1 (2)
   Remdesivir                                   1 (2)
  Immunomodulator                               3 (5)
   Tocilizumab                                  1 (2)
   Rituximab                                    1 (2)
   Ruxolitinib                                  1 (2)
  Hydroxychloroquine                            24 (44)
  *Oxygen therapy (higher intensity), n (%*)    
  Overall                                       30 (54)
   Nasal cannula                                18 (32)
   Non-invasive ventilation                     8 (14)
   Invasive mechanical ventilation              4 (7)
  *Outcomes, n (%*)                             
  Death                                         7 (12)
  ARDS                                          11 (19)
  ICU admission                                 4 (7)
  Hospitalisation (no ICU)                      37 (65)
   Need for rehabilitation                      7 (17)
  *Duration of hospitalisation, median (IQR*)   
  Hospital stay                                 10 (7--22)
   ICU stay                                     16 (10--19)
  Rehab stay                                    14 (11--15)

ARDS, acute respiratory distress syndrome; ICU, intensive care unit.

Clinical outcome in liver transplant patients with COVID-19 {#s3-4}
-----------------------------------------------------------

Overall, 16 (28%, 95% CI 17% to 42%) patients received outpatient care for COVID-19, while 41 (72%, 95% CI 59% to 83%) subjects were hospitalised, with a median (IQR) hospital stay duration of 10 days (7--22). Among hospitalised recipients, 4 (10%, 95% CI 3% to 23%) were admitted to the ICU and required invasive mechanical ventilation, while 11 (19%, 95% CI 10% to 32%) developed ARDS. Death was registered in seven cases (12%, median time from transplant to death was 6 years, IQR 3--13), all of whom were hospitalised with ARDS. Overall, case fatality rate was 12% (95% CI 5% to 24%) in our population, which increased to 17% (95% CI 7% to 32%) among hospitalised patients. General characteristics of patients who did not survive, of those with ARDS and of those who were hospitalised are summarised in [tables 6 and 7](#T6 T7){ref-type="table"}. Five out of the seven patients who died had a history of cancer, of whom three had an active cancer at moment of the diagnosis of COVID-19. Moreover, 9 out of 11 patients with ARDS had a clinical history for cancer. Median (IQR) lymphocyte and platelet counts (×1000/μL) were significantly lower (0.49 (0.30--0.60) vs 0.80 (0.52--1.18), p=0.030; 93 (79-110) vs 170 (104--273), p=0.044, respectively) in the group of patients who did not survive.

###### 

Characteristics of liver transplant recipients died because of COVID-19

  Case                        Sex (M/F)                   Age, years   Ethnicity   BMI, kg/m^2^   Comorbidity                     Symptoms at presentation                     Immunosuppression management   Respiratory support   ICU admission
  --------------------------- --------------------------- ------------ ----------- -------------- ------------------------------- -------------------------------------------- ------------------------------ --------------------- ---------------
  **1**                       M                           67           Caucasian   27.8           History of renal tumour         Fever, cough, dyspnoea                       CNIs alone                     NIMV                  No
  No change                                                                                                                                                                                                                         
  **2**                       M                           78           Caucasian   23.1           History of PTLD                 Fever, cough, dyspnoea                       CNIs alone                     NIMV                  No
  CV disease                  No change                                                                                                                                                                                             
  Diabetes                                                                                                                                                                                                                          
  CKD                                                                                                                                                                                                                               
  **3**                       M                           75           Caucasian   25.1           Active tumour: HCC recurrence   Dyspnoea,                                    CNIs alone                     NIMV                  No
  CV disease                  Fatigue/myalgia             No change                                                                                                                                                                 
  Arterial hypertension                                                                                                                                                                                                             
  **4**                       M                           55           Caucasian   21.6           --                              Fever, dyspnoea                              CNIs+steroids                  NIMV                  No
  Only CNIs discontinuation                                                                                                                                                                                                         
  **5**                       M                           70           Caucasian   28.5           Active tumour: HCC recurrence   Fever, dyspnoea                              CNIs+steroids                  IMV                   Yes
  Arterial hypertension       Only CNIs discontinuation                                                                                                                                                                             
  **6**                       M                           66           Caucasian   23.8           Active tumour: PTLD             Fever, cough, fatigue/myalgia, GI symptoms   Steroids                       IMV                   Yes
  Arterial hypertension       No change                                                                                                                                                                                             
  **7**                       F                           79           Caucasian   21.3           CV disease                      Fever, dyspnoea, fatigue/myalgia             MMF alone                      NC                    No
  Diabetes                                                                                                                                                                                                                          
  Arterial hypertension                                                                                                                                                                                                             
  CKD                                                                                                                                                                                                                               

CKD, chronic kidney disease; CNIs, calcineurin inhibitors; CV, cardiovascular; F, female; IMV, invasive mechanical ventilation; M, male; MMF, mycophenolate mofetil; NC, nasal cannula; NIMV, non-invasive mechanical ventilation; PTLD, post-transplant lymphoproliferative disorder.

###### 

General characteristics of patients who did not survive, of those with ARDS and of those who were hospitalised

  Outcome                                     Overall             Death (n=7)         P value             ARDS (n=11)   P value             Hospitalisation (n=41)   P value                                               
  ------------------------------------------- ------------------- ------------------- ------------------- ------------- ------------------- ------------------------ ------------- ------------------- ------------------- -------------
  Sex, *male*                                 40 (70)             6 (86)              34 (68)             0.662         10 (91)             30 (65)                  0.146         29 (71)             11 (69)             0.883
  Age, *years*, median (IQR)                  65 (57--70)         70 (67--77)         62 (57--70)         0.088         68 (63--73)         62 (55--70)              0.052         65 (57--71)         60 (54--68)         0.162
  BMI, *kg/m^2^*, mean (SD)                   26.0 (21.4--30.6)   24.5 (21.7--27.3)   26.3 (21.4--31.2)   0.185         25.5 (21.6--28.2)   26.2 (21.3--31.1)        0.625         25.5 (29.7--21.4)   27.4 (21.6--33.2)   0.258
  HCC as indication to LT                     20 (35)             5 (71)              15 (30)             0.084         8 (73)              12 (26)                  **0.011**     15 (37)             5 (31)              0.703
  Very long-term LT                           21 (37)             3 (43)              18 (36)             0.701         4 (36)              17 (37)                  1.000         16 (39)             5 (31)              0.582
  Very short-term LT                          11 (19)             2 (29)              9 (18)              0.610         3 (27)              8 (17)                   0.429         9 (22)              2 (13)              0.710
  Smoke history                               7 (14)              1 (17)              6 (14)              1.000         1 (10)              7 (15)                   1.000         5 (14)              2 (14)              1.000
  Cardiovascular disease                      21 (37)             3 (43)              18 (36)             0.700         5 (46)              16 (35)                  0.511         14 (34)             7 (44)              0.502
  Arterial hypertension                       32 (56)             4 (57)              28 (56)             1.000         6 (55)              27 (57)                  1.000         22 (54)             10 (63)             0.544
  Diabetes mellitus                           21 (37)             2 (29)              19 (38)             1.000         4 (36)              17 (36)                  1.000         14 (34)             7 (44)              0.502
  History of cancer                           24 (42)             5 (71)              19 (38)             0.119         9 (82)              15 (33)                  **0.005**     18 (44)             6 (38)              0.659
  Active cancer                               5 (9)               3 (43)              2 (4)               **0.011**     4 (36)              1 (2)                    **0.004**     5 (12)              0 (0)               0.308
  Dyspnoea at presentation                    26 (46)             6 (86)              20 (41)             **0.041**     9 (82)              17 (39)                  **0.016**     22 (54)             4 (27)              0.129
  Leucocytes, *×1000/μ*L, median (IQR)        4.51 (3.33--6.00)   2.95 (1.77--4.51)   4.70 (3.65--6.00)   0.113         3.70 (1.93--5.52)   4.70 (3.65--6.00)        0.297         4.61 (3.39--6.85)   3.85 (3.27--5.13)   0.170
  Platelets, *×1000/μL*, median (IQR)         160 (91--268)       93 (79--110)        170 (104--273)      **0.044**     102 (88--134)       183 (104--280)           0.064         164 (91--270)       149 (96--202)       0.745
  Lymphocytes, *×1000/μL*, median (IQR)       0.79 (0.40--1.10)   0.49 (0.30--0.60)   0.80 (0.52--1.18)   **0.030**     0.49 (0.40--0.76)   0.81 (0.58--1.18)        0.064         0.73 (0.45--1.00)   1.02 (0.74--1.22)   0.126
  AST, *U/L*, median (IQR)                    38 (25--53)         48 (36--80)         35 (24--52)         0.134         38 (27--57)         38 (23--53)              0.358         45 (27--57)         21 (17--29)         **\<0.001**
  ALT, *U/L*, median (IQR)                    30 (20--42)         21 (16--74)         31 (21--42)         0.602         22 (16--30)         32 (22--44)              0.142         33 (23--57)         21 (18--30)         **0.026**
  Overall immunosuppression reduction         22 (39)             2 (29)              20 (40)             0.695         4 (36)              18 (39)                  1.000         18 (44)             4 (25)              0.236
  Overall immunosuppression discontinuation   4 (7)               1 (14)              3 (6)               0.417         1 (9)               3 (7)                    1.000         4 (10)              0 (0)               0.568
  ACE inhibitors or sartans                   13 (24)             3 (50)              10 (20)             0.136         3 (30)              10 (22)                  0.685         10 (25)             3 (20)              1.000
  Oxygen therapy                              30 (54)             7 (100)             23 (47)             **0.012**     11 (100)            19 (42)                  **\<0.001**   29 (71)             1 (7)               **\<0.001**
  Steroids (for COVID-19)                     19 (35)             4 (67)              15 (31)             0.167         6 (60)              13 (29)                  0.077         18 (45)             1 (7)               **0.010**
  Antibiotics                                 35 (63)             7 (100)             28 (57)             **0.038**     10 (91)             25 (57)                  **0.039**     30 (73)             5 (33)              **0.012**
   \>1 antibiotic                             16 (29)             4 (67)              12 (24)             **0.049**     6 (60)              10 (22)                  **0.024**     15 (38)             1 (6)               **0.023**
  Antiviral                                   5 (9)               1 (14)              4 (8)               0.501         1 (9)               4 (9)                    1.000         5 (12)              0 (0)               0.309
  Hydroxychloroquine                          24 (44)             3 (50)              21 (43)             1.000         5 (50)              19 (42)                  0.655         22 (55)             2 (13)              **0.006**

ALT, alanine aminotransferase; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; BMI, body mass index; HCC, hepatocellular carcinoma; LT, liver transplantation; MMF, mycophenolate mofetil,.

Discussion {#s4}
==========

In this observational prospective multicentre study, we report the characteristics, early outcome and management of the COVID-19 outbreak on the largest European cohort of liver transplant patients with confirmed SARS-CoV-2 infection up to date. Case fatality rate of the overall study population was 12% (95% CI 5% to 24%), whereas that of the hospitalised patients was 17% (95% CI 7% to 32%). This latter is in line with that of the general population, as reported by most of the largest studies, where the in-hospital case fatality rate ranges from 15% to 22%.[@R1] All the patients who died, except one, were men. CV disease, obesity, arterial hypertension, diabetes mellitus and chronic kidney disease, although well represented in our population, were not over-represented in the group with adverse outcomes. A clinical history of neoplasia, especially an active cancer at the moment of the diagnosis, was frequently found in the group with a worse prognosis. Recently transplanted patients presented with less fever and respiratory-related symptoms than patients who were transplanted for more than 1 and 5 years, respectively. Among laboratory data, lymphocytopenia and thrombocytopenia were more frequent in patients who died. Alteration in liver enzymes was mild and rarely observed, although mostly found in hospitalised patients. Whether the immunosuppression was decreased or left unchanged had no impact on outcome.

Our study suggests that, despite well-described risk factors for poor outcome of COVID-19 infection are highly represented in our cohort, COVID-19 liver transplant patients show a clinical course not necessarily more severe to that observed in non-liver transplant patients affected by COVID-19.[@R25] Publications pooling patients with different organ transplanted reported worse outcomes (in-hospital case fatality rate 24%--27%).[@R11] Another publication merging surveys from European and American centres with a smaller sample than our prospective study reported 9 deaths among 39 liver transplant patients.[@R28] Like others, we find that male patients are more prone to develop ARDS[@R29] and have a more severe outcome.[@R25] Although highly frequent in our cohort, CV and metabolic comorbidities were not over-represented in patients with poor outcomes.[@R25] History of previous or active cancer, such as being transplanted for HCC or having cancer at the moment of the COVID-19 diagnosis, was associated with a poor outcome. This is in agreement with a national Chinese report on over 2000 confirmed COVID-19 cases with a history of cancer, showing them having higher risk to contract COVID-19 and poorer outcome than individuals without cancer.[@R30]

Concerning clinical presentation, patients transplanted for less than 5 years exhibited less frequently fever and dyspnoea. This may suggest higher immunosuppression attenuates COVID-19 typical clinical symptoms. GI manifestations were common (33%) in our series, which is in line with the 29% reported in solid organ transplant recipients in Spain.[@R11]

Lymphopenia has been reported to be predictive of poor outcome in non-transplanted COVID-19 patients.[@R29] A similar trend was found also in our cohort of liver transplant patients.

One of the key questions in the management of liver transplant patients affected with COVID-19 concerns the management of the immunosuppression.[@R33] In our cohort, the immunosuppression was reduced in 39% of the patients and discontinued in 7%. Mycophenolate mofetil was the most discontinued therapy. The majority of the patients with COVID-19 who did not need a hospitalisation were kept on their usual immunosuppressive regimen. Although some reports want to suggest a potential positive role of tacrolimus as antiviral in the treatment of human coronaviruses,[@R34] since 88% of our patients were treated with CNIs, it was not possible to assess any specific effect of this therapy.

Our study has limitations. All the participating centres are European. It will be important to have similar prospective studies from other continents. We limited our analysis to the patients with a positive reverse transcription PCR for SARS-CoV-2. We did not include patients with typical presentation but without a microbiological confirmation due to lack of testing capacity. On the other hand, the NAAT assay as the recommended confirmatory test has a sensitivity in the order of 71%,[@R35] and this could be lower in immunosuppressed population.[@R13] Moreover, although liver transplant patients were generally well instructed to contact their transplant centre as far as COVID-like symptoms appeared, we cannot exclude a global underestimation of the total number of COVID-19 infections in this population.

Our study has strengths. It is, at the time of writing, the largest prospective study of liver recipient patients affected by COVID-19. It is by design not a survey but a prospective acquisition of data approved by local ethics committees.

In conclusion, in this European multicentre prospective study of liver transplant recipients, COVID-19 is associated with an overall and in-hospital case fatality rate of 12% (95% CI 5% to 24%) and 17% (95% CI 7% to 32%), respectively. Patients infected early after liver transplantation did not have a worse outcome and tend to have less symptoms. A history of cancer was more frequent in patients with poorer outcome.
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